GB2490126A - Opuntia ficus indica, powdered psyllium husk and chitosan composition for reducing fat absorption - Google Patents
Opuntia ficus indica, powdered psyllium husk and chitosan composition for reducing fat absorption Download PDFInfo
- Publication number
- GB2490126A GB2490126A GB1106540.6A GB201106540A GB2490126A GB 2490126 A GB2490126 A GB 2490126A GB 201106540 A GB201106540 A GB 201106540A GB 2490126 A GB2490126 A GB 2490126A
- Authority
- GB
- United Kingdom
- Prior art keywords
- powdered
- weight
- chitosan
- opuntia ficus
- plant material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 32
- 239000010903 husk Substances 0.000 title claims abstract description 23
- 244000134552 Plantago ovata Species 0.000 title claims abstract description 20
- 235000004727 Opuntia ficus indica Nutrition 0.000 title claims abstract description 18
- 240000009297 Opuntia ficus-indica Species 0.000 title claims abstract description 18
- 235000003421 Plantago ovata Nutrition 0.000 title claims abstract description 18
- 239000009223 Psyllium Substances 0.000 title claims abstract description 17
- 229940070687 psyllium Drugs 0.000 title claims abstract description 17
- 238000010521 absorption reaction Methods 0.000 title claims abstract description 10
- 239000002245 particle Substances 0.000 claims abstract description 51
- 241000196324 Embryophyta Species 0.000 claims abstract description 29
- 239000000463 material Substances 0.000 claims abstract description 24
- 239000000843 powder Substances 0.000 claims abstract description 16
- 150000002632 lipids Chemical class 0.000 claims abstract description 11
- 239000002775 capsule Substances 0.000 claims abstract description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 7
- 230000004576 lipid-binding Effects 0.000 claims abstract description 4
- 230000037406 food intake Effects 0.000 claims abstract description 3
- 240000001439 Opuntia Species 0.000 claims description 4
- 241000218218 Ficus <angiosperm> Species 0.000 claims description 3
- 230000027455 binding Effects 0.000 description 7
- 239000003925 fat Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 6
- 235000010451 Plantago psyllium Nutrition 0.000 description 5
- 244000090599 Plantago psyllium Species 0.000 description 5
- 235000013367 dietary fats Nutrition 0.000 description 5
- 241000238557 Decapoda Species 0.000 description 4
- 239000003613 bile acid Substances 0.000 description 4
- 241000219357 Cactaceae Species 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 229920001268 Cholestyramine Polymers 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 241000238424 Crustacea Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241001127637 Plantago Species 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000006196 deacetylation Effects 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 239000002952 polymeric resin Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241001116389 Aloe Species 0.000 description 1
- AFHJQYHRLPMKHU-XXWVOBANSA-N Aloin Natural products O=C1c2c(O)cc(CO)cc2[C@H]([C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)c2c1c(O)ccc2 AFHJQYHRLPMKHU-XXWVOBANSA-N 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 235000017003 Cissus Nutrition 0.000 description 1
- 244000035145 Cissus repens Species 0.000 description 1
- 235000017014 Cissus repens Nutrition 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- 240000001689 Cyanthillium cinereum Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- CPUHNROBVJNNPW-UHFFFAOYSA-N aloin A Natural products OC1C(O)C(O)C(CO)OC1OC1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 CPUHNROBVJNNPW-UHFFFAOYSA-N 0.000 description 1
- AFHJQYHRLPMKHU-WEZNYRQKSA-N aloin B Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@H]1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-WEZNYRQKSA-N 0.000 description 1
- -1 amino polysaccharide Chemical class 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
- 229960002604 colestipol Drugs 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- AFHJQYHRLPMKHU-UHFFFAOYSA-N isobarbaloin Natural products OC1C(O)C(O)C(CO)OC1C1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-UHFFFAOYSA-N 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940041735 rexall Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229930188627 soysaponin Natural products 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A composition for oral ingestion comprising powdered plant material from Opuntia ficus indica, powdered Psyllium (plantago ovata) husk and chitosan. Preferably, the composition comprises 1 to 4 parts by weight (100mg to 400mg) powdered plant material from Opuntia ficus indica; 0.5 to 1.5 part by weight (50mg to 150mg) powdered psyllium husk and 0.5 to 1.5 parts by weight (50mg to 150mg) chitosan. Preferably the powdered plant material from Opuntia ficus indica is derived from leaves of cladodes of the plant in which at least 75% by weight of the powder particles have sizes 230 to 280µm. Preferably the composition is contained within a capsule and is useful for binding lipids passing through the gastrointestinal tract and thereby preventing or reducing absorption of the lipids.
Description
A COMPOSITION FOR REDUCING FAT ABSORPTION
This invention relates to a composition for reducing the absorption of fats from the gastrointestinal tract.
Background of the invention
The incidence of obesity has increased dramatically over the past few decades in most developed countries and one reason for this has been a very large increase in the amount of fat consumed by the average member of the public. A great many solutions to this problem have been proposed ranging from special diets and exercise regimes, lipid-reducing food supplements and diet-suppressing drugs to surgical interventions such as gastric bands.
Various natural, semi-synthetic and synthetic substances have been developed and used for the purpose of binding lipids in the gastrointestinal (01) tract in order to reduce or prevent absorption of the lipids. For example, synthetic polymer resins which may be polyamines or anionic polymeric resins have been proposed and used for binding to bile acids thereby preventing their reuptake and use in the biosynthesis of cholesterol. Examples of substances of this type are disclosed in GB929391 (Merck). A problem with bile acid sequestering resins has been their lack of palatability. Consequently, much research has been expended in finding combinations of the resins with agents that improve the palatability of the resins.
For example, US560 1837 discloses combinations of psyllium husk and cholestyramine for treating hypercholesterolemia. US5286481 discloses combinations of an anion-exchange resin such as cholestyramine, colestipol or polidexide and bran for use in weight-reduction.
Other examples of substances for use in binding bile acids or other lipids such as triglycerides are disclosed in DE4136325 (Hoechst), which discloses cyclodextrins as bile acid adsorption agents useful for treating hyperlipidaemia, and US200410126444 (Dallas etaL), which discloses the use of powdered plant material from the cladodes of cacti for binding dietary fats.
Chitosan has been used for binding and preventing the absorption of dietary fats.
Chitosan is a deacetylated form of chitin, an amino polysaccharide (poly-N-acetyl glucosamine) found in the exoskeleton of arthropods (e.g., crustaceans such as lobsters and crabs) and also found in some plants and fungi. Chitosan is similar in structure and properties to dietary fibre (e.g., vegetable bran, cellulose) but, unlike like bran and cellulose, chitosan has the ability to bind fat and other lipids in the intestine. A known problem with chitosan, as disclosed in W099/21 566 (Rexall Sundown), is that when chitosan is consumed in the quantities required for dietary fat reduction, constipation can result. Indeed, W09912 1566 discloses that the use of chitosan as a dietary supplement must be of short duration or other ingredients or supplements added to combat the undesirable effects of the chitosan.
W099/21566 proposes the addition of aloin, which contains aloe saponins, in order to offset the constipating effect of chitosan. U54999341 discloses the use of soy sapon ins to offset the constipating effect of the chitosan. U52007/0048392 (Oben) discloses the use of combinations of chitosan and a plant extract from a plant of the Cissus, Vernonia or Brillantasia families.
Psyllium seed husks are portions of the seeds of the plant Plantago ovata, (genus Plantago), a native of India. They are soluble in water, expanding and becoming mucilaginous when wet. Psyllium seed husks have also been used for binding dietary fats and preventing their absorption. However, although Psyllium seed husks act as a laxative in relatively small amounts, they can cause constipation when administered in the larger amounts needed for dietary fat removal.
Thus, at present, although numerous substances and combinations of substances have been used for binding dietary lipids in the GI tract so as to prevent uptake of the lipids, many are associated with problems that can limit their effectiveness and the extent to which they are used in many sections of the general population.
Summary of the invention
The present invention provides an improved composition for binding dietary lipids in the GJ tract and thereby preventing or reducing absorption of the Jipids. In this way, the compositions provide a means of combatting obesity and hyperlipidaemia.
Accordingly, in a first aspect, the invention provides a composition for oral ingestion comprising powdered plant material from Opuntia ficus indica; powdered Psyllium husk and chitosan.
The composition may contain from 1 to 4 parts by weight of the powdered plant material from Opuntia ficus indica; from 0.5 to 1.5 parts by weight of powdered Psyllium husk and from 0.5 to 1.5 parts by weight of chitosan.
More particularly, the composition may contain from 100 mg to 400 mg of the powdered plant material from Opuntia ficus indica; from 50 mg to 150 mg of the powdered Psyllium husk and from 50 mg to 150 mg of the chitosan.
For example, the composition may contain from 200 mg to 300 mg of the powdered plant material from Opuntia ficus md/ca; from 75 mg to 125 mg of the powdered Psyllium husk and from 75 mg to 125 mg of the chitosan.
In one preferred embodiment, the composition contains from approximately 250 mg of the powdered leaf material from Opuntia ficus md/ca; approximately 100 mg of the powdered Psyllium husk and approximately 100 mg of the chitosan.
The compositions of the invention may be presented in the form of capsules.
The compositions of the invention may also be presented as medical devices, the term medical device as used herein referring to a substance which whilst providing a medical benefit to a subject, is not absorbed significantly from the subject's GI tract and does not exert its actions by pharmacological means.
The composition, capsule or medical device of the invention as defined herein may be used for binding lipids passing through the gastrointestinal tract and thereby preventing or reducing absorption of the lipids.
Psyllium seed husks are portions of the seeds of the plant Plantago ovata, (genus Plantago), a native of India. They are soluble in water, expanding and becoming mucilaginous when wet.
In the compositions of the present invention, the Psyllium seed husks may be presented in powder form wherein at least 99.5% by weight of the particles forming the powder have a particle size (e.g. diameter) of 600 pM or less. Such particles will pass through a 30 mesh sieve. In one embodiment, at least 99.5% by weight of the particles have a particle size (e.g. diameter) of 400 pM or less. Such particles will pass through a 40 mesh sieve. In another embodiment, at least 99.5% by weight of the particles have a particle size (e.g. diameter) of 300 pM or less. Such particles will pass through a 50 mesh sieve. In a further embodiment, at least 95% by weight of the particles have a particle size (e.g. diameter) of 210 pM or less.
Such particles will pass through a 70 mesh sieve. In another embodiment, at least 75% by weight of the particles will pass through a 50 to 60 mesh sieve and have particle sizes in the range from 230 to 280 pM.
The chitosan used in the compositions of the present invention is produced commercially by deacetylation of chitin, which is the structural element in the exoskeleton of crustaceans (crabs, shrimp, etc.) and cell walls of fungi. The degree of deacetylation is typically in the range 60-1 00 %, for example from 50-90% or 60- 80%. The average molecular weight of the chitosan is typically between 3,800 and 20,000 daltons, for example from 5,000 to 15,000 daltons, or from 5,000 to 10,000 daltons, or from 7,500 to 12,500 daltons..
The chitosan is presented in the form of a powder. The chitosan may be presented in powder form wherein at least 99.5% by weight of the particles forming the powder have a particle size (e.g. diameter) of 600 pM or less. Such particles will pass through a 30 mesh sieve. In one embodiment, at least 99.5% by weight of the particles have a particle size (e.g. diameter) of 400 pM or less. Such particles will pass through a 40 mesh sieve. In another embodiment, at least 99.5% by weight of the particles have a particle size (e.g. diameter) of 300 pM or less. Such particles will pass through a 50 mesh sieve. In a further embodiment, at least 95% by weight of the particles have a particle size (e.g. diameter) of 210 pM or less. Such particles will pass through a 70 mesh sieve. ln another embodiment, at least 75% by weight of the particles will pass through a 50 to 60 mesh sieve and have particle sizes in the range from 230 to 280 pM.
Opuntia ficus indica is a cactus found in Central and South America. The cactus produces "cladodes" or truncated branches of the stem that contain chlorophyll and are adapted to carry out photosynthesis. The cladodes have a leaf-like appearance but are not true leaves. In the present context, the term "leaf material from Opuntia ficus indica" refers to the cladodes.
The term plant material" includes material derived from the cladodes or from other parts of the plant such as the plant stem.
In one preferred embodiment, the plant material is derived from the cladodes or leaves of the plant.
The cladodes or other parts of the plant are dried and then ground to a powder in which at least 99.5% by weight of the particles have a maximum dimension (e.g. S diameter) of less than 300 pM. More typically, at least 70% by weight of the particles have a maximum dimension (e.g. diameter) of less than 100 pM.
Further details of the preparation of powdered plant material from Opuntia ficus indica may be found in US2004/0 126444.
The powdered plant material is presented in the form of a powder. The plant material may be presented in powder form wherein at least 99.5% by weight of the particles forming the powder have a particle size (e.g. diameter) of 600 pM or less.
Such particles will pass through a 30 mesh sieve. In one embodiment, at least 99.5% by weight of the particles have a particle size (e.g. diameter) of 400 pM or less. Such particles will pass through a 40 mesh sieve. In another embodiment, at least 99.5% by weight of the particles have a particle size (e.g. diameter) of 300 pM or less. Such particles will pass through a 50 mesh sieve. In a further embodiment, at least 95% by weight of the particles have a particle size (e.g. diameter) of 210 pM or less. Such particles will pass through a 70 mesh sieve. In another embodiment, at least 75% by weight of the particles will pass through a 50 to 60 mesh sieve and have particle sizes in the range from 230 to 280 pM.
The compositions of the invention are typically administered with or without (but preferably with or shortly before or after) meals one or more times per day. For example, the compositions may be administered from two to four times per day.
The compositions may be administered so that the daily intakes of the three components are as follows: Powdered plant material from Opuntia ficus indica: 100 mg to 1600 mg Powdered Psyllium husk: 50 mg to 600 mg Chitosan: 50 mg to 600 mg The compositions of the invention bind fats and other lipids in the GI tract and carry them through so that they are excreted with the faeces. In this way, the fats and other lipids cannot be absorbed by the body. By mopping up a large proportion of the fats in food consumed by a subject, obesity and hyperlipidaemia may be prevented.
The invention will now be illustrated but not limited, by reference to the following
specific example.
EXAMPLE I
Capsule formulation I Into a two part capsule shell formed from hydroxypropyl methylcellu lose is filled a mixture of powdered Opuntia ficus indica, Psyllium husk and chitosan in the following proportions: Opuntia ficus indica powder 250 mg Pysyllium husk powder 100 mg chitosan powder 100 mg The capsules are taken as a food supplement, two capsules being administered with each meal up to a total of six capsules per day.
It will readily be apparent that numerous modifications and alterations may be made to the specific embodiments of the invention described above without departing from the principles underlying the invention. All such modifications and alterations are intended to be embraced by this application.
Claims (12)
- CLAIMS1. A composition for oral ingestion comprising powdered plant material from Opuntia ficus indica; powdered Psyllium husk and chitosan.
- 2. A composition according to claim I comprising from I to 4 parts by weight of the powdered plant material from Opuntia ficus indica; from 0.5 to 1.5 parts by weight of powdered Psyllium husk and from 0.5 to 1.5 parts by weight of chitosan.
- 3. A composition according to claim 2 containing from 100 mg to 400 mg of the powdered plant material from Opuntia ficus indica; from 50 mg to 150 mg of the powdered Psyllium husk and from 50 mg to 150 mg of the chitosan.
- 4. A composition according to claim 3 containing from 200 mg to 300 mg of the powdered plant material from Opuntia ficus indica; from 75 mg to 125 mg of the powdered Psyllium husk and from 75 mg to 125 mg of the chitosan.
- 5. A composition according to claim 4 containing from approximately 250 mg of the powdered plant material from Opuntia ficus indica; approximately 100 mg of the powdered Psyllium husk and approximately 100 mg of the chitosan.
- 6. A composition according to any one of claims I to 5 wherein the powdered plant material from Opuntia ficus md/ca is derived from leaves or cladodes of the plant.
- 7. A composition according to any one of claims I to 6 wherein the powdered plant material from Opuntia f/cus md/ca is presented in the form of a powder in which at least 75% by weight of the particles have particle sizes in the range from 230 to 280 pM.
- 8. A composition according to any one of claims I to 7 wherein the powdered Psyllium husk is presented in the form of a powder in which at least 75% by weight of the particles have particle sizes in the range from 230 to 280 pM.
- 9. A composition according to any one of claims I to 8 wherein the chitosan is presented in the form of a powder in which at least 75% by weight of the particles have particle sizes in the range from 230 to 280 pM.
- 10. A capsule containing a composition according to any one of claims I to 9.
- 11. A medical device comprising a composition according to any one of claims I to9.
- 12. A composition, capsule or medical device according to any one of claims I to 11 for use in binding lipids passing through the gastrointestinal tract and thereby preventing or reducing absorption of the lipids.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1106540.6A GB2490126A (en) | 2011-04-18 | 2011-04-18 | Opuntia ficus indica, powdered psyllium husk and chitosan composition for reducing fat absorption |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1106540.6A GB2490126A (en) | 2011-04-18 | 2011-04-18 | Opuntia ficus indica, powdered psyllium husk and chitosan composition for reducing fat absorption |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB201106540D0 GB201106540D0 (en) | 2011-06-01 |
| GB2490126A true GB2490126A (en) | 2012-10-24 |
Family
ID=44147173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1106540.6A Withdrawn GB2490126A (en) | 2011-04-18 | 2011-04-18 | Opuntia ficus indica, powdered psyllium husk and chitosan composition for reducing fat absorption |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2490126A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2501242A (en) * | 2012-03-23 | 2013-10-23 | Ajit Ramanial Patel | A composition for the treatment of obesity |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001047372A2 (en) * | 1998-07-10 | 2001-07-05 | Vanson, Inc. | Absorbing fat chitosan |
| US20020137729A1 (en) * | 2000-07-21 | 2002-09-26 | Babish John G. | Combinations of psyllium and chitosan for synergistic adsorption of triglyceride |
| US20040126444A1 (en) * | 2001-04-11 | 2004-07-01 | D'huart Jean-Baptiste | Cactaceae-based formulation having the property of fixing fats and method for obtaining same |
| KR20100084027A (en) * | 2009-01-15 | 2010-07-23 | 세종대학교산학협력단 | Composition of nanochitosan for lowering cholesterol and triglyceride in blood |
| US20100323045A1 (en) * | 2007-11-06 | 2010-12-23 | Finzelberg Gmbh & Co. Kg | Extract formulation of opuntia ficus indica |
-
2011
- 2011-04-18 GB GB1106540.6A patent/GB2490126A/en not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001047372A2 (en) * | 1998-07-10 | 2001-07-05 | Vanson, Inc. | Absorbing fat chitosan |
| US20020137729A1 (en) * | 2000-07-21 | 2002-09-26 | Babish John G. | Combinations of psyllium and chitosan for synergistic adsorption of triglyceride |
| US20040126444A1 (en) * | 2001-04-11 | 2004-07-01 | D'huart Jean-Baptiste | Cactaceae-based formulation having the property of fixing fats and method for obtaining same |
| US20100323045A1 (en) * | 2007-11-06 | 2010-12-23 | Finzelberg Gmbh & Co. Kg | Extract formulation of opuntia ficus indica |
| KR20100084027A (en) * | 2009-01-15 | 2010-07-23 | 세종대학교산학협력단 | Composition of nanochitosan for lowering cholesterol and triglyceride in blood |
Non-Patent Citations (3)
| Title |
|---|
| http://web.archive.org/web/20081026094448/http://www.neopuntia.com/uk/Lipophilic-properties_2_9.html available online 26 October 2008 (wayback machine) accessed 2 August 2012 * |
| Journal of Medicine, vol. 33, No 1-4, 2002, pages 209-225 * |
| The Journal of Nutrition, vol. 135, No. 10, 2005, pages 2399-2404 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2501242A (en) * | 2012-03-23 | 2013-10-23 | Ajit Ramanial Patel | A composition for the treatment of obesity |
Also Published As
| Publication number | Publication date |
|---|---|
| GB201106540D0 (en) | 2011-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1679009B1 (en) | Pharmaceutical and dietetic compositions based on vegetable fibres | |
| Avachat et al. | Recent investigations of plant based natural gums, mucilages and resins in novel drug delivery systems | |
| Holdt et al. | Bioactive compounds in seaweed: functional food applications and legislation | |
| Quirós-Sauceda et al. | Dietary fiber and phenolic compounds as functional ingredients: interaction and possible effect after ingestion | |
| Madgulkar et al. | Characterization of psyllium (Plantago ovata) polysaccharide and its uses | |
| US20180325941A1 (en) | Composition for reducing absorption of dietary fat | |
| US5932561A (en) | Dietary composition with lipid binding properties for weight management and serum lipid reduction | |
| Arora et al. | Plant-based polysaccharides and their health functions | |
| US20100216719A1 (en) | Soluble Fiber Combinations for Weight Control and Improving Parameters of Cardiovascular Health | |
| Sharma et al. | Natural polymers-promising potential in drug delivery | |
| GB2501242A (en) | A composition for the treatment of obesity | |
| Muruganantham et al. | Gums as Pharmaceutical Excipients: An Overview | |
| GB2490126A (en) | Opuntia ficus indica, powdered psyllium husk and chitosan composition for reducing fat absorption | |
| Sharma et al. | Use of natural superdisintegrant in mouth dissolving tablet-an emerging trend | |
| Rasmussen et al. | Chitin and chitosan | |
| ES2812148T3 (en) | Preparation for body weight control based on chitosan and cellulose | |
| Manjili et al. | Composite alginate-based hydrogel delivery of antioxidant pumpkin protein hydrolysate in simulated gastrointestinal condition | |
| Purohit et al. | Isabgol: a herbal remedy | |
| EP4044824A1 (en) | Nutritional supplement | |
| Jun et al. | Anti-obesity effects of chitosan and psyllium husk with L-ascorbic acid in guinea pigs | |
| Sari et al. | The Potential of Polysaccharides from Various Plants as Constipation Treatment | |
| Singh et al. | Development of fiber rich powder and effect of supplementation on constipation | |
| Pal et al. | Properties of plant polysaccharides used as pharmaceutical excipients | |
| DE102017108054A1 (en) | Edible composition for digestion promotion | |
| GB2501241A (en) | A composition for reducing obesity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |